Kubota N, Nomoto M, Hwang GW, Watanabe T, Kohara M, Wakita T, Naganuma A, Kuge S. Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication. World J Hepatol 2016; 8(5): 282-290 [PMID: 26925202 DOI: 10.4254/wjh.v8.i5.282]
Corresponding Author of This Article
Shusuke Kuge, Professor, Department of Microbiology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi 981-8558, Japan. skuge@tohoku-pharm.ac.jp
Research Domain of This Article
Virology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Naoko Kubota, Masataka Nomoto, Gi-Wook Hwang, Akira Naganuma, Shusuke Kuge, Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi 980-8578, Japan
Toshihiko Watanabe, Shusuke Kuge, Department of Microbiology, Tohoku Pharmaceutical University, Miyagi 981-8558, Japan
Michinori Kohara, Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-0057, Japan
Takaji Wakita, Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
Author contributions: Kubota N, Nomoto M and Watanabe T performed the experiments; Hwang GW, Kohara M, Naganuma A and Kuge S designed the research study; Wakita T provided the JFH1/HCVcc system; Kuge S wrote the report; all of the authors critically read and commented on the article.
Institutional review board statement: No Ethics Committee approval was required.
Informed consent statement: No Ethics Committee approval was required.
Conflict-of-interest statement: All of the authors have no conflict of interest to declare in relationship to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shusuke Kuge, Professor, Department of Microbiology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, Miyagi 981-8558, Japan. skuge@tohoku-pharm.ac.jp
Telephone: +81-22-7270129 Fax: +81-22-7270129
Received: September 29, 2015 Peer-review started: October 1, 2015 First decision: November 4, 2015 Revised: December 3, 2015 Accepted: January 16, 2016 Article in press: January 19, 2016 Published online: February 18, 2016 Processing time: 139 Days and 16.5 Hours
Core Tip
Core tip: Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. Several non-structural proteins of HCV physically and functionally interact with heat-shock protein 90 (HSP90). Although HSP90 inhibitors, which inhibit the chaperone function of HSP90, have been shown to inhibit HCV replication by several groups, a recent report using a reporter system for HCV RNA replication (replicon) suggests that the effect is nonspecific. Thus, the inhibitory mechanism of HSP90 inhibitors remains controversial. Here, we address the effect of HSP90 inhibitors on the release of JFH1/cell culture-derived HCV from Huh-7 cells, and suggested that, HSP90 inhibitors may also interfere with an HCV replication step that occurs after the synthesis of viral RNA, such as assembly and release.
